Harvard Bioscience Announces Third Quarter Financial Results

11/6/19

HOLLISTON, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced financial results for the three and nine months ended September 30, 2019.

The Company reported revenue of $27.4 million for the third quarter of 2019, with an operating loss of $(1.4) million and EPS of $(0.07). On an adjusted basis, gross margin was 55.6%, operating income measured $3.3 million or 12.1% of sales, and adjusted diluted EPS was $0.04. Cash flow from operations for the nine months ended September 30, 2019 was $5.8 million compared to $0.3 million for the comparable prior year period.

Jim Green, Chairman and CEO said, “We are executing on our strategic priorities. In spite of Q3 revenue continuing at a slower pace, adjusted operating margin improved by 90 basis points, all while taking initial actions designed to meet the targets outlined for next year’s profitability and growth. As revenue headwinds annualize in the first half of next year, we expect improvements in sales effectiveness combined with product improvements to yield organic growth in line with our published targets.”

Green continued, “Cellular and Molecular Technologies related products saw continued organic growth in our CRISPR related applications and in precision infusion pumps. North America and APAC sales grew, while EMEA declined on timing of large equipment sales, resulting in a modest decline in organic revenue globally for the product family.”

Green continued, “Sales of Pre-Clinical Systems products sold into CROs and Pharma improved in North America, with revenue from CROs returning to historical run-rates. However, overall Pre-Clinical Systems revenue was down on declines in APAC.”

Green concluded, “We will continue to take the necessary actions to strengthen our business. Although we expect continued soft revenue trends in Q4, we anticipate significant adjusted operating margin improvement in the quarter. For the full year 2019, we expect revenues to be in the range of $116-$118 million, slightly lower than previous expectations. We anticipate adjusted gross margin, adjusted operating margin and adjusted diluted EPS to be 56%, 12%-13%, and $0.19, respectively, in line with our previous guidance. We believe the disciplined action plan we are executing is positioning the business to be significantly stronger next year. Recently executed actions include enhancing the senior leadership team and making cost structure improvements, including completing the consolidation of the Raleigh, North Carolina operations.”

Third Quarter Reported Results

Revenue for the three months ended September 30, 2019 was $27.4 million, a decrease of 4%, or $1.2 million, compared to revenue of $28.6 million for the three months ended September 30, 2018.

Operating loss for the three months ended September 30, 2019 was $(1.4) million, a decrease of $2.3 million, compared to operating income of $0.9 million for the three months ended September 30, 2018. The operating loss for the period included $2.2 million of costs associated with the CEO transition in July 2019 and initial site and product line consolidation activities aligned with profitability initiatives announced in September 2019.

Adjusted operating income was $3.3 million for the three months ended September 30, 2019, an increase of approximately 4%, or $0.1 million, compared to $3.2 million for the three months ended September 30, 2018. The increase in adjusted operating income was the result of improved product mix coupled with strong cost management, more than offsetting the impact of lower revenue.

Net loss was $(0.07) per share for the three months ended September 30, 2019, compared to a net loss of $(0.01) per share for the same quarter in 2018.

Adjusted diluted earnings per share was $0.04 for the three months ended September 30, 2019, same as the three months ended September 30, 2018.

Please refer to Exhibit 4 below for a reconciliation of certain non-GAAP to GAAP financial measures, including revenue, gross profit, operating expenses, operating income and loss, net income and loss, and diluted earnings per share. As to our 2019 guidance referenced in this release, please refer to Exhibit 5 below for reconciliations of the GAAP diluted earnings per share and adjusted diluted earnings per share, GAAP gross margin and adjusted gross margin and GAAP operating margin and adjusted operating margin. Please see “Use of Non-GAAP Financial Information” for additional information regarding our use of such adjusted financial information.

Balance Sheet and Cash Flow

As of September 30, 2019, cash was $6.8 million and total debt was $54.3 million. Cash flow from operations for the nine months ended September 30, 2019 was $5.8 million, funding the majority of the $6.8 million reduction in total debt since December 31, 2018.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.